Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Bruno Mars tour 2026: How to get tickets for 'The Romantic Tour,' presale times, prices and more - 2Death toll from floods in Afghanistan rises to 61
- 3Woman charged in unprovoked stabbing of tourist changing baby's diaper in Macy’s Herald Square store
- 4Finding the Universe of Workmanship: Individual Encounters in Imagination
- 5After toilet and email issues, Artemis II astronauts fire engine to head for the moon
- France honors the victims of the Paris attacks' night of terror 10 years on
- Mossad unveils network of Hamas terror infrastructure across Europe
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- Kids may be more likely to get the new ‘Cicada’ variant of Covid-19, scientists say. Here’s what to know about BA.3.2
- The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- True to life Authenticity d: A Survey of \Certifiable Stories\ Narrative
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
